|
Press Releases |
|
 |
|
Friday, June 13, 2025 |
|
Jacobson Pharma Announces FY2025 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period"). more info >> |
|
Friday, November 22, 2024 |
|
Jacobson Pharma Announces FY2025 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines and specialty drugs, today announced the interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 September 2024 (the "Reporting Period"). more info >> |
|
Friday, November 25, 2022 |
|
Jacobson Pharma Announces FY2023 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2022 (the "Reporting Period"). more info >> |
|
Wednesday, June 29, 2022 |
|
Jacobson Pharma Announces FY2022 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period"). more info >> |
|
Wednesday, June 15, 2022 |
|
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia |
Ban Loong Holdings Limited ("Ban Loong", together with its subsidiaries, "Ban Loong Group"; stock code: 0030.HK), of which Yunnan Baiyao Group Co., Ltd. (stock code: 000538.SHE) is the controlling shareholder, Jacobson Pharma Corporation Limited ("Jacobson", together with its subsidiaries (excluding JBM Group) more info >> |
|
Monday, March 14, 2022 |
|
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60% |
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited (the "Company"; together with its subsidiaries, the "Group"; Stock Code: 2633), a leading company engaged in the research more info >> |
|
Friday, November 26, 2021 |
|
Jacobson Pharma Announces FY2022 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines more info >> |
|
Tuesday, June 29, 2021 |
|
Jacobson Pharma Announces FY2021 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products more info >> |
|
Friday, February 5, 2021 |
|
JBM (Healthcare) Limited Debuts on The Main Board of SEHK |
JBM (Healthcare) Limited ("JBM Healthcare" or "Company", together with its subsidiaries, the "Group"), a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries, started trading today on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") under stock code 2161. more info >> |
|
Monday, January 25, 2021 |
|
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited |
JBM (Healthcare) Limited ("JBM Healthcare" or "Company" and, together with its subsidiaries, the "Group"), a Hong Kong-based company that markets and distributes branded healthcare products with product footprint across Greater China, Southeast Asia and certain other countries, today announced details of the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK"). more info >> |
|
|
|
|
|
|